Sign in
CompletedNo phase

Clinical Trial of a Hydrophilic EMV Toric Lens RAO210T in the Correction of Aphakia and Corneal Astigmatism

Key facts

Who runs it
Rayner Intraocular Lenses Limited
Where
Alexandria, Avon, Fayetteville, Grand Junction, Kansas City, Mt. Pleasant, San Antonio, Sioux Falls, and West Fargo, United StatesSee the 9 sites
Trial code
Status
Completed
People taking part
274 people enrolled
Started
10 Aug 2023
Ended
23 Oct 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • RayOne EMV Toric IOL
  • RayOne Monofocal IOL
  • Cataract Surgery
Record updated
21 January 2026

Who can take part

Age
22 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Male or female, 22 years or older at the pre-operative visit who have cataract with best corrected distance visual acuity of 0.30 logMAR (20/40) or worse in at least one eye with or without a glare source present who are eligible for phacoemulsification cataract surgery
  • Subjects who are projected to have best corrected distance visual acuity 0.20 logMAR (20/30) or better after IOL implantation by potential acuity meter (PAM) or Investigator estimation
  • Clear intraocular media other than cataract
  • Contact lens wearers must demonstrate stability of biometry
  • Have the capability to understand and sign an IRB approved informed consent form and privacy authorization in accordance with local regulations
  • Female subjects must be 1-year postmenopausal, surgically sterilized, or, if of childbearing potential, have a negative urine pregnancy test at the Pre-operative Visit. Women of childbearing potential must use an acceptable form of contraception throughout the study; Acceptable methods include at least one of the following: intrauterine (intrauterine device), hormonal (oral, injection, patch, implant, ring), barrier with spermicide (condom, diaphragm), or abstinence
  • Have Investigator selected IOL spherical equivalent power between +10.0 D to +25.0 D in 0.5 D steps and IOL cylinder power of +1.50 D
  • Have pre-existing corneal astigmatism of 1.00 D to 1.50 D as determined by keratometry
  • Dilated pupil size 5.5 mm or greater to allow visualization of the toric IOL axis markings post-operatively

Who cannot take part

  • Previous intraocular, corneal, or retinal detachment surgery, including corneal transplant, LASIK / LASEK / PRK, SMILE, astigmatic keratotomy and limbal relaxing incisions in the planned operative eye
  • Subjects reasonably expected to require secondary ocular surgical intervention or laser treatment (other than YAG capsulotomy)
  • Participating in a concurrent drug or device clinical trial or who have participated in a drug or device trial within 30 days of the pre-operative visit
  • Use of medications known to interfere with visual performance, pupil dilation, or iris structure within 30 days of the pre-operative visit, at the discretion of the Investigator
  • Diagnosed degenerative visual disorders (e.g. macular degeneration, retinal detachment, proliferative diabetic retinopathy, or other retinal disorders) that are predicted to cause future acuity losses to a level of 0.20 logMAR (20/30) or worse
  • Significant anterior segment pathology that might increase intraoperative risk or compromise IOL stability (e.g. pseudoexfoliation syndrome, any iris pathology)
  • Subjects with conditions associated with increased risk of zonular rupture (that may affect post-operative centration or tilt of IOL) in the planned operative eye
  • Subjects with any other serious ocular pathology (e.g. glaucoma, severe dry eye, history of intraocular inflammation, history of retinal surgery or retinal laser procedure) or underlying systemic medical condition (e.g., uncontrolled diabetes) or circumstance that, based on the Investigator's judgment, poses a concern for the subjects' safety or could confound the results of the study (History of cataract surgery with PC-IOL in one eye is allowed.)
  • Potentially occludable angle or ciliary body tumor, or other pathology that might increase risk to subject safety, based on gonioscopic observation
  • Subjects with clinically significant corneal pathology, potentially affecting corneal topography
  • Subjects with traumatic cataract in the planned operative eye
  • Pregnant or nursing females
  • Irregular astigmatism in the planned operative eye

Where in United States

  • Vance Thompson Vision AlexandriaAlexandria, United States
  • Cleveland Eye ClinicAvon, United States
  • Vold VisionFayetteville, United States
  • Icon EyeCareGrand Junction, United States
  • Moyes Eye CenterKansas City, United States
  • Carolina Eyecare PhysiciansMt. Pleasant, United States
  • Parkhurst NuVisionSan Antonio, United States
  • Vance Thompson VisionSioux Falls, United States
  • Vance Thompson Vision North DakotaWest Fargo, United States

About the trial

What the trial wants to find out

The objectives of the clinical investigation are to determine the safety and performance of the RayOne EMV Toric (Model RAO210T) following unilateral implantation and approximately 6 months (120 to 180 days) of post-operative assessment, as a randomized comparison to aspheric monofocal control for low cylinder (1.50 D). This patient population with cataracts and low corneal cylinder (+1.00 to +1.50 D) will have the natural crystalline lens removed and replaced with an intraocular lens in the capsular bag.

The 2 groups in the trial

  • Toric (test) groupTreatment being tested

    All subjects randomized to be implanted with the low cylinder (1.50 D) RayOne EMV Toric IOL (Model RAO210T)

    Treatment: RayOne EMV Toric IOL and Cataract Surgery

  • Monofocal (control) groupExisting treatment, for comparison

    All subjects randomized to be implanted with the RAO600C Monofocal IOL

    Treatment: RayOne Monofocal IOL and Cataract Surgery

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Trial to Investigate the Safety and Effectiveness of a Hydrophilic EMV Toric Lens RAO210T in the Correction of Aphakia and Post-operative Corneal Astigmatism
Record updated
21 January 2026